Activist Shareholders Complicate Buyout Math
Executive Summary
The efforts of an increasingly vocal group of activist shareholders, including Carl Icahn, Matrix Asset Advisors, Third Point, ValueAct, and Baker Brothers Advisors, to flush out the interest of strategic buyers has become compelling and increasingly commonplace.
You may also be interested in...
Capital Allocation In The Age Of Shareholder Activism
Maybe no company is safe from activists, but there are protective measures that managers and boards can take. What biopharmas can learn from Valeant Pharmaceuticals and Pershing Square’s pursuit of Allergan.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2007
In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for April-June 2007. Our data come from Windhover's Strategic Transactions Database. Look for our quarterly review on the medical device, in vitro diagnostics, and research industries in upcoming issues.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2007
In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for April-June 2007. Our data come from Windhover's Strategic Transactions Database. Look for our quarterly review on the medical device, in vitro diagnostics, and research industries in upcoming issues.